Sort   by:  
 Page size 
UnknownInflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.
Not available
S-EPMC4911309 | biostudies-literature
UnknownRethinking medulloblastoma from a targeted therapeutics perspective.
Not available
S-EPMC6132970 | biostudies-literature
UnknownOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Not available
S-EPMC5649550 | biostudies-literature
UnknownExpression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.
Not available
S-EPMC4157573 | biostudies-literature
UnknownManagement of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2.
Not available
S-EPMC7570235 | biostudies-literature
UnknownGenomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
Not available
S-EPMC4334774 | biostudies-literature
UnknownPhase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Not available
S-EPMC5363293 | biostudies-literature
UnknownAntitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Not available
S-EPMC9306456 | biostudies-literature
UnknownClinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma.
Not available
S-EPMC12352890 | biostudies-literature
UnknownEconomic Evaluation of Quality Improvement Interventions Designed to Prevent Hospital Readmission: A Systematic Review and Meta-analysis.
Not available
S-EPMC5710454 | biostudies-literature
Sort   by:  
 Page size